May 2 |
Xencor (XNCR) Moves 14.3% Higher: Will This Strength Last?
|
Apr 29 |
Why Clever Leaves Holdings Shares Are Trading Lower By Around 60%? Here Are Other Stocks Moving In Monday's Mid-Day Session
|
Apr 24 |
Calliditas Therapeutics' 2023 Annual Report Published
|
Apr 24 |
Calliditas Announces Positive NefIgArd Open Label Extension Results
|
Apr 18 |
Calliditas Therapeutics Presents Additional Data Analyses from the Phase 3 NeflgArd trial of Nefecon in Primary IgA Nephropathy at the ISN World Congress of Nephrology 2024
|
Apr 16 |
Novartis (NVS) Presents Positive Data on Rare Kidney Disease Drug
|
Apr 9 |
Calliditas Therapeutics to Attend Conferences in April
|
Apr 8 |
Calliditas Therapeutics to Present Nefecon Data at the ISN World Congress of Nephrology April 13 - 16 in Buenos Aires
|
Apr 8 |
Calliditas receives notice of allowance for United States patent application covering setanaxib in cancer treatment
|
Mar 12 |
Everest Medicines' Partner Calliditas Therapeutics Announces U.S. FDA Grants an Additional Seven-Year Orphan Drug Exclusivity Period for Nefecon®
|